$2.6 Billion is the total value of Avoro Capital Advisors LLC's 44 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 70.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $152,865,000 | +10.2% | 1,622,770 | -5.2% | 5.88% | -11.2% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $146,346,000 | +2.4% | 9,369,150 | -1.4% | 5.63% | -17.5% |
| TGTX | Sell | TG THERAPEUTICS INC | $65,093,000 | -12.3% | 4,950,031 | -5.3% | 2.51% | -29.3% |
| ARGX | Sell | ARGENX SEsponsored adr | $64,801,000 | -6.7% | 782,053 | -9.4% | 2.50% | -24.8% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $52,128,000 | -15.3% | 1,146,436 | -1.7% | 2.01% | -31.7% |
| PCRX | Sell | PACIRA PHARMACEUTICALS INC | $46,813,000 | -12.4% | 1,460,610 | -14.8% | 1.80% | -29.4% |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $37,776,000 | -29.7% | 963,427 | -11.9% | 1.45% | -43.4% |
| MDCO | Sell | MEDICINES CO | $35,290,000 | -34.5% | 961,574 | -41.2% | 1.36% | -47.2% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS INC | $31,665,000 | -62.9% | 700,548 | -60.3% | 1.22% | -70.1% |
| DERM | Sell | DERMIRA INC | $16,945,000 | -38.1% | 1,841,823 | -46.3% | 0.65% | -50.2% |
| CPRX | Sell | CATALYST PHARMACEUTICALS INC | $14,031,000 | +25.1% | 4,497,042 | -4.2% | 0.54% | +0.7% |
| ONSIZ | Exit | ONCOBIOLOGICS INC - WARRANT Bwarrant | $0 | – | -233,333 | -100.0% | -0.00% | – |
| MGNX | Exit | MACROGENICS INCcall | $0 | – | -14,500 | -100.0% | -0.00% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INCcall | $0 | – | -162,500 | -100.0% | -0.01% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INCcall | $0 | – | -500,000 | -100.0% | -0.02% | – |
| VCYT | Exit | VERACYTE INC | $0 | – | -119,680 | -100.0% | -0.03% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INCcall | $0 | – | -152,000 | -100.0% | -0.07% | – |
| QURE | Exit | UNIQURE NVshares | $0 | – | -67,758 | -100.0% | -0.08% | – |
| SLDB | Exit | SOLID BIOSCIENCES INC | $0 | – | -275,000 | -100.0% | -0.10% | – |
| AGEN | Exit | AGENUS INC | $0 | – | -704,554 | -100.0% | -0.16% | – |
| DOVA | Exit | DOVA PHARMACEUTICALS INC | $0 | – | -125,000 | -100.0% | -0.16% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INCcall | $0 | – | -2,350,100 | -100.0% | -0.18% | – |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -783,910 | -100.0% | -0.19% | – |
| VRAY | Exit | VIEWRAY INC | $0 | – | -730,161 | -100.0% | -0.19% | – |
| VIVE | Exit | VIVEVE MEDICAL INC | $0 | – | -1,533,276 | -100.0% | -0.27% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -317,100 | -100.0% | -0.34% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -396,635 | -100.0% | -0.36% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -560,658 | -100.0% | -0.36% | – |
| STML | Exit | STEMLINE THERAPEUTICS INC | $0 | – | -524,321 | -100.0% | -0.38% | – |
| AVEO | Exit | AVEO PHARMACEUTICALS INC | $0 | – | -3,231,893 | -100.0% | -0.45% | – |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -523,174 | -100.0% | -0.56% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -750,300 | -100.0% | -1.25% | – |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -1,024,124 | -100.0% | -1.26% | – |
| ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -1,922,655 | -100.0% | -1.50% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -1,650,700 | -100.0% | -1.56% | – |
| ARMO | Exit | ARMO BIOSCIENCES INC | $0 | – | -1,207,500 | -100.0% | -2.16% | – |
| AVXS | Exit | AVEXIS INC | $0 | – | -675,262 | -100.0% | -3.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.